Plus Therapeutics (NASDAQ:PSTV) Upgraded at Wall Street Zen

Plus Therapeutics (NASDAQ:PSTV) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Several other research firms have also recently commented on PSTV. HC Wainwright restated a “buy” rating and issued a $1.00 target price (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Lake Street Capital started coverage on shares of Plus Therapeutics in a research note on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price objective on the stock. Finally, D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.60.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV opened at $3.56 on Friday. The company has a market cap of $24.42 million, a PE ratio of -0.11 and a beta of 1.03. The company’s 50-day moving average price is $0.39 and its 200 day moving average price is $0.50. Plus Therapeutics has a fifty-two week low of $3.23 and a fifty-two week high of $30.50.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Thursday, March 12th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.28. The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $1.23 million. As a group, equities analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current year.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. L1 Global Manager Pty Ltd bought a new position in shares of Plus Therapeutics during the 4th quarter valued at about $1,167,000. Geode Capital Management LLC raised its holdings in shares of Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics in the 4th quarter worth approximately $525,000. Altium Capital Management LLC acquired a new stake in Plus Therapeutics during the third quarter valued at approximately $628,000. Finally, Virtu Financial LLC acquired a new stake in Plus Therapeutics during the fourth quarter valued at approximately $254,000. 3.28% of the stock is owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.